Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- TWST +18.5%, TH +6.8% (extends contract; reaffirms guidance), BRC +2.4%, NIU +0.5%
Other news:
- RGNX +30.8% (initiates AFFINITY DUCHENNE trial of RGX-202; announced new positive efficacy and safety data from the Phase I/II portion of the study)
- ADVM +16.6% (topline 52-week results from the LUNA Phase 2 trial, new 4-year OPTIC long-term follow-up data and key pivotal program design elements)
- CYBN +12.5% (Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder)
- SMCI +11.2% (Barron's article)
- TUYA +11.2% (enters anchor investment by 65 Equity Partners)
- RYTM +10.1% (Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide)
- ALDX +9.3% (FDA has accepted for review the resubmitted New Drug Application for topical ocular reproxalap)
- NTLA +7.7% (Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis)
- SNDX +6.8% (FDA approves revumenib, a menin inhibitor, for relapsed or refractory acute leukemia)
- TSLA +6.5% (President-elect Trump wants to ease regulations on self-driving cars)
- FOUR +6% (to join S&P MidCap 400)
- WOLF +5.7% (announces leadership transition; Gregg Lowe to depart as President & CEO and as a Member of the Board of Directors)
- CAAS +4.8% (approved a share repurchase program of up to $5 million of its outstanding common shares periodically over the next 12 months)
- LWAY +4.4% (confirms that it has received a revised, unsolicited, non-binding proposal from Danone (DANOY) North America PBC to acquire all outstanding shares of common stock of Lifeway it does not already own for $27.00 per share in cash)
- SIGA +4% (CDC says California confirms first clade I mpox case)
- SAVE +3.7% (enters comprehensive agreement to deleverage balance sheet; receives backstopped commitments for $350 million equity investment and $300 million in debtor-in-possession financing)
- CABA +3.6% (Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024)
- HY +3.2% (authorized the repurchase of up to $50 million or 1.5 million shares)
- ARWR +3% (new results from the Phase 3 PALISADE study and the open-label extension from the Phase 2 MUIR and SHASTA-2 studies of investigational plozasiran)
- LRMR +2.8% (data from the Company's Phase 1 studies and the Phase 2 dose exploration study of nomlabofusp)
- RILY +1.9% (B Riley Financial and funds managed by Oaktree Capital Management announce the launch of a partnership between B. Riley and Oaktree in the Great American Group)
- CVS +1.7% (confirms Board appointments; Appointments follow productive engagement with Glenview Capital Management)
- UCTT +1.6% (insider bought 15,000 shares at $34.50 - $35.00 worth almost $523K)
- CATX +1.3% (to discuss data on [212Pb]VMT-a-NET presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024)
- BMRN +1% (Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024)
- GL +1% (approved an authorization to repurchase up to $1.8 billion of common stock)